Development of gemcitabine-resistant patient-derived xenograft models of pancreatic ductal adenocarcinoma

Abstract

Aim: Gemcitabine is a frontline agent for locally-advanced and metastatic pancreatic ductal adenocarcinoma (PDAC), but neither gemcitabine alone nor in combination produces durable remissions of this tumor type. We developed three PDAC patient-derived xenograft (PDX) models with gemcitabine resistance (gemR) acquired in vivo, with which to identify mechanisms of resistance relevant to drug exposure in vivo and to evaluate novel therapies.

Methods: Mice bearing independently-derived PDXs received 100 mg/kg gemcitabine once or twice weekly. Tumors initially responded, but regrew on treatment and were designated gemR. We used immunohistochemistry to compare expression of proteins previously associated with gemcitabine resistance [ribonucleotide reductase subunit M1 (RRM1), RRM2, human concentrative nucleoside transporter 1 (hCNT1), human equilibrative nucleoside transporter 1 (hENT1), cytidine deaminase (CDA), and deoxycytidine kinase (dCK)] in gemR and respective gemcitabine-naïve parental tumors.

Results: Parental and gemR tumors did not differ in tumor cell morphology, amount of tumor-associated stroma, or expression of stem cell markers. No consistent pattern of expression of the six gemR marker proteins was observed among the models. Increases in RRM1 and CDA were consistent with in vitro-derived gemR models. However, rather than the expected decreases of hCNT1, hENT1, and dCK, gemR tumors expressed no change in or higher levels of these gemR marker proteins than parental tumors.

Conclusion: These models are the first PDAC PDX models with gemcitabine resistance acquired in vivo. The data indicate that mechanisms identified in models with resistance acquired in vitro are unlikely to be the predominant mechanisms when resistance is acquired in vivo. Ongoing work focuses on characterizing unidentified mechanisms of gemR and on identifying agents with anti-tumor efficacy in these gemR models.

Keywords

Gemcitabine resistance / patient-derived xenograft / ribonucleotide reductase subunit M1 / ribonucleotide reductase subunit M2 / human concentrative nucleoside transporter 1 / human equilibrative nucleoside transporter 1 / cytidine deaminase / deoxycytidine kinase

References

[1] Siegel RL,Jemal A.Cancer statistics, 2019..CA Cancer J Clin2019;69:10

[2] Maitra A.Pancreatic cancer..Annu Rev Pathol2008;3:157-88 PMCID:PMC2666336

[3] Burris H.Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil..Eur J Cancer.1997;33 Suppl 1:S18-22

[4] Burris HA3rd,Andersen J,Rothenberg ML.Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial..J Clin Oncol1997;15:2403-13

[5] Berlin J.Chemotherapy: gemcitabine remains the standard of care for pancreatic cancer..Nat Rev Clin Oncol2010;7:135-7

[6] de Sousa Cavalcante L.Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer..Eur J Pharmacol2014;741:8-16

[7] Nakano Y,Koizumi K,Nakamura K.Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells..Br J Cancer2007;96:457-63 PMCID:PMC2360025

[8] Amrutkar M.Pancreatic cancer chemoresistance to gemcitabine..Cancers (Basel)2017;9: PMCID:PMC5704175

[9] Zeng S,Lan B,Pilarsky C.Chemoresistance in Pancreatic Cancer..Int J Mol Sci2019;20: PMCID:PMC6770382

[10] Cascioferro S,Parrino B,Funel N.Imidazo[2,1-b] [1,3,4]thiadiazoles with antiproliferative activity against primary and gemcitabine-resistant pancreatic cancer cells..Eur J Med Chem2020;189:112088

[11] Bhutia YD,Patel B,Govindarajan R.CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells..Cancer Res2011;71:1825-35 PMCID:PMC3048166

[12] Nordh S,Andersson R.hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: a systematic review..World J Gastroenterol2014;20:8482-90 PMCID:PMC4093699

[13] Spratlin J,Glubrecht D,Young JD.The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma..Clin Cancer Res2004;10:6956-61

[14] Bergman AM,Peters GJ.Determinants of resistance to 2’,2’-difluorodeoxycytidine (gemcitabine)..Drug Resist Updat2002;5:19-33

[15] Sebastiani V,Rubio-Viqueira B,Yeo CJ.Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival..Clin Cancer Res2006;12:2492-7 PMCID:PMC3619210

[16] Tibaldi C,Tiseo M,Barbieri F.Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer: a prospective validation study..Br J Cancer2018;119:1326-31 PMCID:PMC6265283

[17] Liang C,Meng Q,Ji S.Complex roles of the stroma in the intrinsic resistance to gemcitabine in pancreatic cancer: where we are and where we are going..Exp Mol Med2017;49:e406 PMCID:PMC5750480

[18] Duxbury MS,Zinner MJ,Whang EE.Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells..Clin Cancer Res2004;10:2307-18

[19] Ng SSW,Chow S.Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells..Cancer Res2000;60:5451-5

[20] Hu G,Ouyang K,Tang X.Intrinsic gemcitabine resistance in a novel pancreatic cancer cell line is associated with cancer stem cell-like phenotype..Int J Oncol2012;40:798-806

[21] Vaz AP,Seshacharyulu P.A concise review on the current understanding of pancreatic cancer stem cells..J Cancer Stem Cell Res2014;2: PMCID:PMC4594952

[22] Singh S,Bhardwaj A,Singh AP.CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy..Br J Cancer2010;103:1671-9 PMCID:PMC2994230

[23] Schniewind B,Kurdow R,Kremer B.Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria-mediated apoptosis..Int J Cancer2004;109:182-8

[24] Shi X,Kleeff J,Buchler MW.Acquired resistance of pancreatic cancer cells towards 5-Fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes..Oncology2002;62:354-62

[25] Garcia PL,Christein JD,Heslin MJ.Development and histopathological characterization of tumorgraft models of pancreatic ductal adenocarcinoma..PLoS One2013;8:e78183 PMCID:PMC3806809

[26] Jin K,Shen Y,Xu Z.Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review..Clin Transl Oncol2010;12:473-80

[27] Morelli MP,Ordonez E,Viqueira BR.Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft..J Clin Oncol2012;30:e45-8 PMCID:PMC4874230

[28] Von Hoff DD,Arena FP,Infante J.Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine..N Engl J Med2013;369:1691-703 PMCID:PMC4631139

[29] Tentler JJ,Weekes CD,Leong S.Patient-derived tumour xenografts as models for oncology drug development..Nat Rev Clin Oncol2012;9:338-50 PMCID:PMC3928688

[30] Garcia PL,Kreitzburg KM,Gamblin TL.The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models..Oncogene2016;35:833-45 PMCID:PMC6713275

[31] Garcia PL,Gamblin TL,Christein JD.JQ1 induces DNA damage and apoptosis, and inhibits tumor growth in a patient-derived xenograft model of cholangiocarcinoma..Mol Cancer Ther2018;17:107-18 PMCID:PMC5752593

[32] Miller AL,Garcia PL,Council LN.The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors..EBioMedicine2019;44:419-30 PMCID:PMC6604668

[33] Kreitzburg KM,Landen CN,Vance RB.FTY720 enhances the anti-tumor activity of carboplatin and tamoxifen in a patient-derived xenograft model of ovarian cancer..Cancer Lett2018;436:75-86 PMCID:PMC6756795

[34] Houghton PJ,Tucker C,Favours E.The pediatric preclinical testing program: description of models and early testing results..Pediatr Blood Cancer2007;49:928-40

[35] Samulitis BK,Pond E,Patel H.Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors..Cancer Biol Ther2015;16:43-51 PMCID:PMC4623403

[36] Davidson JD,Flagella M,Gelbert LM.An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines..Cancer Res2004;64:3761-6

[37] Jonckheere N,Merlin J,Dumont P.The mucin MUC4 and its membrane partner ErbB2 regulate biological properties of human CAPAN-2 pancreatic cancer cells via different signalling pathways..PLoS One2012;7:e32232 PMCID:PMC3290552

[38] Minami K,Yamamoto M,Zhang S.Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors..J Pharmacol Sci2015;127:319-25

[39] Wang C,Fu M,Huang H.Establishment of human pancreatic cancer gemcitabineresistant cell line with ribonucleotide reductase overexpression..Oncol Rep2015;33:383-90

[40] Achiwa H,Sato S,Niimi T.Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer..Cancer Sci2004;95:753-7

[41] Garcia-Manteiga J,Casado FJ,Pastor-Anglada M.Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2’,2’-difluorodeoxycytidine- induced cytotoxicity..Clin Cancer Res2003;9:5000-8

[42] Mackey JR,Selner M,Young JD.Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines..Cancer Res1998;58:4349-57

[43] Neff T.Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine..Exp Hematol1996;24:1340-6

[44] Ohhashi S,Mizumoto K,Egami T.Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer..Anticancer Res2008;28:2205-12

[45] Saiki Y,Fujimura H,Kudo Y.DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells..Biochem Biophys Res Commun2012;421:98-104

[46] Weizman N,Shabtay-Orbach A,Binenbaum Y.Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase..Oncogene2014;33:3812-9

[47] Gzil A,Bursiewicz W,Grzanka D.Markers of pancreatic cancer stem cells and their clinical and therapeutic implications..Mol Biol Rep2019;46:6629-45

[48] Sergeant G,Gremeaux L.Role of cancer stem cells in pancreatic ductal adenocarcinoma..Nat Rev Clin Oncol2009;6:580-6

[49] Duong HQ,Kim HJ,Seong YS.Aldehyde dehydrogenase 1A1 confers intrinsic and acquired resistance to gemcitabine in human pancreatic adenocarcinoma MIA PaCa-2 cells..Int J Oncol2012;41:855-61 PMCID:PMC3508685

[50] van Diest PJ,Baak JP.Prognostic value of proliferation in invasive breast cancer: a review..J Clin Pathol2004;57:675-81 PMCID:PMC1770351

[51] Hausser HJ.Phenotypic instability of Saos-2 cells in long-term culture..Biochem Biophys Res Commun2005;333:216-22

[52] Kelland LR.Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development..Eur J Cancer2004;40:827-36

[53] Bergman AM,Ruiz van Haperen VW,Veerman G.In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant..Cancer Res2005;65:9510-6

[54] Corbett TH,Roberts BJ,Schabel FM Jr.Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure..Cancer Res1975;35:2434-9

[55] Peters GJ,Nadal JC,Lankelma J.Diurnal variation in the therapeutic efficacy of 5-fluorouracil against murine colon cancer..In Vivo1987;1:113-7

[56] Ter Brugge P,van der Burg E,de Maaker M.Mechanisms of therapy resistance in patient-derived xenograft models of BRCA1-deficient breast cancer..J Natl Cancer Inst2016;108:

[57] Yu J,Moyer AM,Thompson KJ.Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study..Breast Cancer Res2017;19:130 PMCID:PMC5719923